Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Given Average Rating of "Hold" by Brokerages
Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Given Average Rating of "Hold" by Brokerages
Turning Point Therapeutics, Inc. (NASDAQ:TPTX – Get Rating) has received an average rating of "Hold" from the twelve brokerages that are covering the stock, Marketbeat reports. Eight research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $78.22.
據Marketbeat報道,Turning Point Treateutics,Inc.(納斯達克代碼:TPTX-GET評級)已從報道該股的12家券商那裏獲得“持有”的平均評級。8名研究分析師對該股的評級為持有,3名分析師對該公司的評級為買入。在過去一年發佈該股報告的分析師中,平均12個月的價格目標是78.22美元。
Several research firms have recently commented on TPTX. SVB Leerink lowered Turning Point Therapeutics from an "outperform" rating to a "market perform" rating and reduced their price objective for the stock from $101.00 to $76.00 in a research note on Monday, June 13th. Guggenheim set a $76.00 target price on shares of Turning Point Therapeutics in a report on Monday, June 20th. Cowen downgraded shares of Turning Point Therapeutics from an "outperform" rating to a "market perform" rating in a report on Monday, June 6th. Wells Fargo & Company downgraded shares of Turning Point Therapeutics from an "overweight" rating to an "equal weight" rating and set a $76.00 target price for the company. in a report on Friday, June 3rd. Finally, Cowen downgraded shares of Turning Point Therapeutics from an "outperform" rating to a "market perform" rating in a report on Monday, June 6th.
幾家研究公司最近對TPTX發表了評論。SVB Leerink在6月13日(星期一)的一份研究報告中將Turning Point Treateutics的評級從“跑贏大盤”下調至“市場表現”,並將該股的目標價從101.00美元下調至76美元。古根海姆在6月20日星期一的一份報告中為Turning Point Treeutics的股票設定了76.00美元的目標價。在6月6日星期一的一份報告中,考恩將Turning Point Treateutics的股票評級從“跑贏大盤”下調至“市場表現”。富國銀行將Turning Point Treateutics的股票評級從增持下調至持平,併為該公司設定了76.00美元的目標價。在6月3日星期五的一份報告中。最後,考恩在6月6日星期一的一份報告中將Turning Point治療公司的股票評級從“跑贏大盤”下調至“市場表現”。
Insider Buying and Selling at Turning Point Therapeutics
轉折點治療公司的內部買入和賣出
In other Turning Point Therapeutics news, CFO Paolo Tombesi sold 1,183 shares of the stock in a transaction dated Wednesday, July 27th. The shares were sold at an average price of $74.94, for a total transaction of $88,654.02. Following the completion of the transaction, the chief financial officer now owns 28,700 shares of the company's stock, valued at approximately $2,150,778. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 8.60% of the company's stock.
在Turning Point Treeutics的其他消息中,首席財務官保羅·湯貝西在7月27日星期三的交易中出售了1183股該公司股票。這些股票的平均價格為74.94美元,總成交金額為88,654.02美元。交易完成後,首席財務官現在擁有28,700股公司股票,價值約2,150,778美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的,可以通過美國證券交易委員會網站訪問該文件。內部人士持有該公司8.60%的股份。
Institutional Inflows and Outflows
機構資金流入和流出
Turning Point Therapeutics Trading Up 0.7 %
轉折點治療公司股價上漲0.7%
Shares of TPTX opened at $76.01 on Monday. The firm has a market cap of $3.81 billion, a PE ratio of -11.02 and a beta of -0.18. Turning Point Therapeutics has a 1-year low of $23.77 and a 1-year high of $82.20. The firm has a fifty day simple moving average of $75.49 and a two-hundred day simple moving average of $54.27.
TPTX的股票週一開盤報76.01美元。該公司市值為38.1億美元,市盈率為-11.02倍,貝塔係數為-0.18倍。Turning Point Treeutics的一年低點為23.77美元,一年高位為82.20美元。該公司的50日簡單移動均線為75.49美元,200日簡單移動均線為54.27美元。
Turning Point Therapeutics (NASDAQ:TPTX – Get Rating) last posted its quarterly earnings data on Monday, August 8th. The company reported ($2.48) EPS for the quarter, missing the consensus estimate of ($1.78) by ($0.70). The firm had revenue of $0.12 million during the quarter, compared to analysts' expectations of $2.27 million. Turning Point Therapeutics's quarterly revenue was down 97.7% compared to the same quarter last year. During the same period last year, the business earned ($1.14) EPS. As a group, research analysts forecast that Turning Point Therapeutics will post -7.69 EPS for the current fiscal year.
Turning Point Treateutics(納斯達克代碼:TPTX-GET Rating)上一次公佈季度收益數據是在8月8日星期一。該公司公佈本季度每股收益(2.48美元),低於(1.78美元)和(0.70美元)的普遍預期。該公司本季度營收為12萬美元,高於分析師預期的227萬美元。與去年同期相比,Turning Point Treateutics的季度收入下降了97.7%。去年同期,該業務每股收益為1.14美元。作為一個整體,研究分析師預測,Turning Point Treateutics本財年的每股收益將達到7.69歐元。
Turning Point Therapeutics Company Profile
轉折點治療公司簡介
(Get Rating)
(獲取評級)
Turning Point Therapeutics, Inc, a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients.
Turning Point治療公司是一家臨牀階段的精確腫瘤學生物製藥公司,致力於設計和開發針對癌症遺傳驅動因素的治療方法。它開發了一系列酪氨酸激酶抑制劑(TKI),針對TKI-NAI、̈Ve和TKI預治療患者的癌症基因驅動因素。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on Turning Point Therapeutics (TPTX)
- Kroger's is Your One-Stop Consumer Staples Stock
- Adobe Perfects the Art of the Faceplant for Investors
- Tax Credits are the Incentives in the Inflation Reduction Act
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- 免費獲取StockNews.com關於轉折點治療(TPTX)的研究報告
- 克羅格百貨是你的一站式消費者史泰博股票
- Adobe為投資者完善Facebook工廠的藝術
- 税收抵免是《降低通貨膨脹法案》中的激勵措施
- 第四季度值得考慮的3家銀行
- 股市:紅海中的三座強國
Receive News & Ratings for Turning Point Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turning Point Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《轉折點治療日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Turning Point Treateutics和相關公司的最新新聞和分析師評級的每日簡要摘要。